Venture capital firm Legend Capital led a $227m Series B funding round in RecBio, a Chinese biotech company. Additional investors include Lyfe Capital, Sequoia Capital, Vertex Ventures, HT Capital, Co-Stone Asset Management, Yuanbio Venture Capital, Qingsong Capital, and China Everbright. RecBio will use the capital injection to build a base for the industrialization of its major products and to conduct clinic tests of the 9-valent HPV vaccine and recombinant Covid vaccine. The startup is also looking to further develop its product and expand its business to the global market.